CPHA Canvax
CPHA Canvax

"An elevated risk for myocarditis among mRNA COVID-19 vaccines has been observed, particularly in males aged 12–29 years. On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination to individual persons and at the population level clearly outweighed the risks of myocarditis after vaccination. Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected. Information regarding the risk for myocarditis with mRNA COVID-19 vaccines should be disseminated to providers to share with vaccine recipients." - United States Centers for Disease Control and Prevention

Additional Authors: Matthew E. Oster, Karen R. Broder, Julianne Gee, Eric Weintraub, Tom Shimabukuro, Heather M. Scobie, Danielle Moulia, Lauri E. Markowitz, Melinda Wharton, Veronica V. McNally, José R. Romero, H. Keipp Talbot, Grace M. Lee,
Matthew F. Daley, Sara E. Oliver


Related Resources





Vaccine Safety and Development,Vaccine Safety,Vaccine Safety,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccine Safety and Development
Vaccine Safety
Vaccine Safety
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Outbreaks and Pandemics


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.